 Antibodies, Monoclonal
"Antibodies, Monoclonal" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antibodies produced by a single clone of cells.
| Descriptor ID |
D000911
|
| MeSH Number(s) |
D12.776.124.486.485.114.224 D12.776.124.790.651.114.224 D12.776.377.715.548.114.224
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Monoclonal".
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Monoclonal".
This graph shows the total number of publications written about "Antibodies, Monoclonal" by people in this website by year, and whether "Antibodies, Monoclonal" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 3 | 13 | 16 | | 1996 | 6 | 13 | 19 | | 1997 | 5 | 5 | 10 | | 1998 | 2 | 14 | 16 | | 1999 | 7 | 7 | 14 | | 2000 | 7 | 9 | 16 | | 2001 | 11 | 16 | 27 | | 2002 | 7 | 16 | 23 | | 2003 | 8 | 11 | 19 | | 2004 | 12 | 17 | 29 | | 2005 | 16 | 14 | 30 | | 2006 | 17 | 14 | 31 | | 2007 | 20 | 11 | 31 | | 2008 | 10 | 20 | 30 | | 2009 | 35 | 20 | 55 | | 2010 | 26 | 21 | 47 | | 2011 | 12 | 17 | 29 | | 2012 | 11 | 14 | 25 | | 2013 | 14 | 10 | 24 | | 2014 | 33 | 10 | 43 | | 2015 | 10 | 10 | 20 | | 2016 | 14 | 13 | 27 | | 2017 | 24 | 15 | 39 | | 2018 | 20 | 10 | 30 | | 2019 | 18 | 8 | 26 | | 2020 | 24 | 11 | 35 | | 2021 | 18 | 9 | 27 | | 2022 | 6 | 25 | 31 | | 2023 | 5 | 19 | 24 | | 2024 | 15 | 15 | 30 | | 2025 | 17 | 6 | 23 |
To return to the timeline, click here.
Below are the most recent publications written about "Antibodies, Monoclonal" by people in Profiles.
-
Sun Y, Fujiwara Y, Torphy RJ, Yee EJ, Guo Y, Sun Z, Hu J, Eck E, Terai T, Schulick RD, Zhu Y. CD93 blockade overcomes sunitinib resistance in pancreatic neuroendocrine tumors. Mol Ther. 2025 Oct 01; 33(10):5017-5027.
-
Muro K, Feinstein T, Baranda J, Bonta I, Yanagitani N, Gersten T, Gandhi L, Kudo T, Fujioka N, Kaplan J, Gorla S, Liu S, Wozniak M, Poondru S, Dillon R, Meng C, Patil T. Enfortumab vedotin in patients with advanced non-small cell lung cancer after disease progression on platinum- and PD-1/PD-L1 inhibitor-containing regimens: Phase 2 international multicenter EV-202 study. Eur J Cancer. 2025 Sep 09; 227:115603.
-
Knowlton KU, Siegel LK, Barkauskas CE, Bhagani S, Dharan NJ, Gardner EM, Gottlieb RL, Helleberg M, Highbarger HC, Holland TL, Heerfordt CK, Lazarte S, Leither LM, Lutaakome J, Ardelt M, Mylonakis E, Ong SWX, Overcash JS, Taha H, Tien PC, Trautner BW, Vallee D, Weintrob AC, Touloumi G, Babiker AG. Passive immunotherapy for adults hospitalized with COVID-19: An individual participant data meta-analysis of six randomized controlled trials. PLoS Med. 2025 Jul; 22(7):e1004616.
-
Aggarwal C, Martinez-Marti A, Majem M, Barlesi F, Carcereny E, Chu Q, Monnet I, Sánchez-Hernández A, Dakhil S, Camidge DR, Pillet M, Brown M, Paliompeis C, Dowson A, Cooper ZA, Kumar R, Herbst RS. Durvalumab Alone or Combined With Novel Agents for Unresectable Stage III Non-Small Cell Lung Cancer: Update From the COAST Randomized Clinical Trial. JAMA Netw Open. 2025 07 01; 8(7):e2518440.
-
Carlisle TC, Bateman JR, Yang Y, Lachner C, Stockbridge MD, Flashman LA, Chemali Z, Alzbeidi N, Pressman PS, Osibajo AM, Bobrin BD, Martinez-Menendez CJ, Teixeira AL, Daffner KR. Antiamyloid Monoclonal Antibodies in Alzheimer's Disease, Part 2: Challenges in Dementia Care Delivery System Logistics. J Neuropsychiatry Clin Neurosci. 2025; 37(4):378-384.
-
Fish LE, Roberts SC, Bennett TD, Carlson NE, Hamer MK, Kwan BM, Russell S, Wogu AF, Wynia MK, Ginde AA. Experiences of recently diagnosed urban COVID-19 outpatients: A survey on patient worries, provider-patient interactions, and neutralizing monoclonal antibody treatment. PLoS One. 2025; 20(6):e0325991.
-
Cash T, Marachelian A, DuBois SG, Chi YY, Baregamyan A, Groshen SG, Jonus HC, Shamirian A, Crowley M, Goodarzian F, Acharya PT, Pawel B, Erbe AK, Shahi A, Zaborek J, Kennedy E, Asgharzadeh S, Villablanca JG, Pinto N, Weiss BD, Mosse YP, Desai AV, Macy ME, Granger M, Vo KT, Sondel PM, Matthay KK, Park JR, Goldsmith KC. Phase I Study of 131I-Metaiodobenzylguanidine With Dinutuximab ± Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial. J Clin Oncol. 2025 Aug; 43(22):2490-2501.
-
Paller AS, Soong W, Boguniewicz M, Geng B, Thyssen JP, Bennike N, Schneider S, Wollenberg A. Effect of tralokinumab on moderate-to-severe atopic dermatitis in patients with atopic comorbidities. Ann Allergy Asthma Immunol. 2025 Oct; 135(4):425-433.e4.
-
Guaschino V, Santarsiero D, Gastoldi S, Thurman JM, Holers VM, Violette SM, Liu F, Fahnoe KC, Guarinoni C, Benigni A, Remuzzi G, Noris M, Aiello S. C3d-targeted complement inhibitors to correct complement dysregulation in aHUS patients. Front Immunol. 2025; 16:1620996.
-
Filsinger Interrante MV, Tang S, Kim S, Shanker VR, Hie BL, Bruun TUJ, Wu W, Pak JE, Fernandez D, Kim PS. Utilizing Machine Learning to Improve Neutralization Potency of an HIV-1 Antibody Targeting the gp41 N-Heptad Repeat. ACS Chem Biol. 2025 Jul 18; 20(7):1470-1480.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|